Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chromosomal Rearrangement”

111 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 111 results

Testing effectiveness (Phase 2)Study completedNCT03037385
What this trial is testing

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+37 more
Hoffmann-La Roche 590
Not applicableStudy completedNCT02520895
What this trial is testing

Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
LYMPHOMA
Hospices Civils de Lyon 98
Early research (Phase 1)Looking for participantsNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Testing effectiveness (Phase 2)Study completedNCT03701295
What this trial is testing

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Who this might be right for
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLLeukemia CutisRecurrent Acute Myeloid Leukemia+1 more
National Cancer Institute (NCI) 1
Early research (Phase 1)Ended earlyNCT03182257
What this trial is testing

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Who this might be right for
Solid Tumor
Ono Pharmaceutical Co., Ltd. 1
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Testing effectiveness (Phase 2)Looking for participantsNCT05727176
What this trial is testing

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Who this might be right for
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc. 120
Early research (Phase 1)Looking for participantsNCT06001788
What this trial is testing

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AMLAML With Mutated NPM1Hematologic Malignancy+9 more
Kura Oncology, Inc. 171
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Testing effectiveness (Phase 2)Ended earlyNCT02186821
What this trial is testing

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

Who this might be right for
Tumors With Aberrations in ALK or ROS1
Novartis Pharmaceuticals 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)WithdrawnNCT05718297
What this trial is testing

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Who this might be right for
NSCLC, Stage IIIALK-rearrangement
ETOP IBCSG Partners Foundation
Not applicableStudy completedNCT02451761
What this trial is testing

Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability

Who this might be right for
Intellectual DisabilityCongenital Abnormalities
Hospices Civils de Lyon 55
Not applicableLooking for participantsNCT07133789
What this trial is testing

The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopmental Disorders

Who this might be right for
Anomalies Chromosome
Assistance Publique - Hôpitaux de Paris 105
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Testing effectiveness (Phase 2)Looking for participantsNCT05118789
What this trial is testing

Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid Tumor
Nuvalent Inc. 359
Not applicableActive Not RecruitingNCT06424379
What this trial is testing

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

Who this might be right for
Non Hodgkin LymphomaFollicular LymphomaMarginal Zone Lymphoma+1 more
Hospices Civils de Lyon 135
Testing effectiveness (Phase 2)UnknownNCT03608007
What this trial is testing

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Who this might be right for
Lung CancerROS1 Gene Rearrangement
Betta Pharmaceuticals Co., Ltd. 69
Load More Results